Q32 Bio announced new 36-week and initial 16-week off-drug results from its Phase 2a SIGNAL-AA trial of bempikibart, a novel antibody treatment for severe alopecia areata. These findings, to be presented at the European Academy of Dermatology and Venereology Congress, suggest sustained hair regrowth and highlight the drug's unique immune-targeting mechanism. The data reinforce Q32 Bio's commitment to developing innovative therapies for autoimmune diseases and will be shared with the scientific community for further validation.
Q32 Bio's clinical trial results for bempikibart in alopecia areata provide context for health sector activity. For readers following health stocks, 56 of 95 US health-sector stocks on Pluang rose while 25 fell. Notable movers include ABEO at USD 5.46 with a -1.97% change, TXG at USD 78.08 with a +1.93% change, and RXRX at USD 3.90 with a +1.83% change. This data is as of Sep 21, 2026 20:01 WIB.
Alkermes plc's drug ALKS7290 demonstrated significant improvement in ADHD symptoms in a Phase 1b trial, with patients showing a 14- to 19-point gain on a 54-point scale within two weeks. This outperforms typical placebo effects, which range from 6 to...
Morgan Stanley upgraded NNN REIT from Neutral to Overweight due to its stable income and strong financial health. The REIT boasts a 99.1% occupancy rate and 97.5% fixed-rate debt, ensuring steady rental income and protection against interest rate hik...
On September 21, 2026, Sandisk was added to the S&P 100 index, replacing Nike, which was removed on the same day. This change reflects shifts in market capitalization and company performance within the index. The update is significant for investors t...
Several top analysts, including Cantor Fitzgerald, Guggenheim, Morgan Stanley, and BTIG Research, have raised price targets and upgraded their outlooks for ServiceNow, signaling confidence in the company's long-term growth. Despite this, the stock ha...
Nebius Group has been upgraded to a buy rating following a significant improvement in its operating margin, which nearly broke even in the second fiscal quarter after a -32% loss in the first quarter. This turnaround is attributed to capacity expansi...
